Pre-operative enhanced magnetic resonance imaging combined with clinical features predict early recurrence of hepatocellular carcinoma after radical resection

doi:10.4251/wjgo.v16.i4.1192

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1753)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-5) series.

Item

Count

PDF

HTML

943

Figures (1-2)

173

Tables (1-5)

144

Sum=1305

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

298

Sum=392

Apr 15, 2024 (publication date) through Jan 11, 2025

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastrointest Oncol. Apr 15, 2024; 16(4): 1192-1203
Published online Apr 15, 2024. doi: 10.4251/wjgo.v16.i4.1192

Table 1 Clinical data of hepatocellular carcinoma patients with early or non-early recurrence after resection, n (%)

Factors		Early recurrence, n = 73 (%)	Non-early recurrence, n = 88 (%)	χ²/t	P value
Age (yr)	-	53.47 ± 11.07	59.88 ± 9.76	-3.902	0.000^b
Serum albumin	-	40.43 ± 4.21	40.05 ± 5.27	0.501	0.617
Total bilirubin	-	17.24 ± 10.52	18.62 ± 8.84	-0.903	0.368
Gender	Male	62 (84.9)	80 (90.9)	1.370	0.242
	Female	11 (15.1)	8 (9.1)	-	-
Age (group)	> 50	43 (58.9)	76 (86.4)	17.679	0.000^b
	≤ 50	30 (41.1)	12 (13.6)	-	-
Hepatitis B	Positive	72 (98.6)	81 (92.0)	Fisher	0.073
	Negative	1 (1.4)	7 (8.0)	-	-
Cirrhosis	Present	40 (54.8)	50 (56.8)	0.066	0.797
	Absent	33 (45.2)	38 (43.8)	-	-
HBV-DNA	Negative	12 (16.4)	19 (21.6)	0.681	0.409
	Positive	61 (83.6)	69 (78.4)	-	-
AFP	> 100	44 (60.3)	30 (34.1)	11.013	0.001^b
	≤ 100	29 (39.7)	58 (65.9)	-	-
Child-Pugh score	A	68 (93.2)	74 (84.1)	3.146	0.076
	B	5 (6.8)	14 (15.9)	-	-
Portal hypertension	Present	23 (31.5)	27 (30.7)	0.013	0.910
	Absent	50 (68.5)	61 (69.3)	-	-
Operation mode	Local excision	21 (28.8)	34 (38.6)	2.261	0.133
	Anatomical excision	52 (71.2)	54 (61.4)	-	-
Postoperative HAIC	Present	13 (17.8)	11 (12.5)	0.886	0.346
	Absent	60 (82.2)	77 (87.5)	-	-
BCLC stage	0	3 (4.1)	9 (10.2)	26.919	0.000^b
	A	29 (39.7)	62 (70.5)	-	-
	B	15 (20.5)	11 (12.5)	-	-
	C	26 (35.6)	6 (6.8)	-	-
CNLC stage	I	31 (42.5)	72 (81.8)	29.060	0.000^b
	II	16 (21.9)	10 (11.4)	-	-
	III	26 (35.6)	6 (6.8)	-	-
Degree of pathological differentiation	Low	10 (13.7)	15 (17.0)	3.397	0.183
	Middle	62 (84.9)	67 (76.1)	-	-
	High	1 (1.4)	6 (6.8)	-	-
Pathological satellite focus	Present	15 (20.5)	6 (6.8)	6.631	0.010^b
	Absent	58 (79.5)	82 (93.2)	-	-
MVI	Present	39 (53.4)	17 (19.3)	20.461	0.000^b
	Absent	33 (46.6)	71 (80.7)

^bP < 0.01.

HBV: Hepatitis B virus; AFP: Alpha-fetoprotein; HAIC: Hepatic artery infusion chemotherapy; BCLC: Barcelona Clinic Liver Cancer; CNLC: China liver cancer; MVI: Microvascular invasion.

Table 2 Magnetic resonance imaging features in hepatocellular carcinoma patients with early or non-early recurrence after resection, n (%)

Factors		Early recurrence, n = 73 (%)	Non-early recurrence n = 88 (%)	χ²/t	P value
Max-diameter		6.85 ± 3.78	5.19 ± 3.52	2.918	0.004^b
Tumor SI/peritumoral SI		50.67 ± 12.20	57.63 ± 15.64	-3.097	0.002^b
Tumor numbers	Single	51 (69.9)	75 (85.2)	5.536	0.019^a
	Multiple	22 (30.1)	13 (14.8)
Tumor boundary	Regular	20 (27.4)	61 (69.3)	28.049	0.000^b
	Irregular	53 (72.6)	27 (30.7)
Portal vein tumor thrombus	Present	13 (17.8)	2 (2.3)	Fisher	0.001^b
	Absent	60 (82.2)	86 (97.7)
Large vessel invasion	Present	26 (35.6)	5 (5.7)	22.997	0.000^b
	Absent	47 (64.4)	83 (94.3)
Intratumoral hemorrhage	Present	23 (31.5)	16 (18.2)	3.860	0.049^a
	Absent	50 (68.5)	72 (81.8)
Intratumoral necrosis	Present	52 (71.2)	36 (40.9)	14.804	0.000^b
	Absent	21 (28.8)	52 (59.1)
Tumor steatosis	Present	6 (8.2)	15 (17.0)	2.741	0.098
	Absent	67 (91.8)	73 (83.0)
Tumor capsule	Intact	20 (27.4)	55 (62.5)	20.220	0.000^b
	Incomplete	42 (57.5)	24 (27.3)
	Lack	11 (15.1)	9 (10.2)
HBP peritumoral high uptake	Present	0 (0.0)	5 (5.7)	Fisher	0.064
	Absent	73 (100.0)	83 (94.3)
Nonrim arterial phase hyperenhancement	Present	73 (100.0)	86 (97.7)	Fisher	0.501
	Absent	0 (0.0)	2 (2.3)
Nonperipheral washout	Present	68 (93.2)	72 (81.8)	4.518	0.034^a
	Absent	5 (6.8)	16 (18.2)
Peritumoral enhancement	Present	18 (24.7)	9 (10.2)	5.953	0.015^a
	Absent	55 (75.3)	79 (89.9)
HBP peritumoral low signal	Present	26 (35.6)	7 (8.0)	18.736	0.000^b
	Absent	47 (64.4)	81 (92.0)
Peritumoral delay enhancement	Present	5 (6.8)	27 (30.7)	14.231	0.000^b
	Absent	68 (92.2)	61 (69.3)

^aP < 0.05.

^bP < 0.01.

SI: Signal intensity; HBP: Hepatobiliary phase.

Table 3 Univariate logistic regression analysis in hepatocellular carcinoma patients with early or non-early recurrence after resection

Factors	B	SE	Wald χ²	P value	HR	95%CI
Age (group)	1.486	0.391	14.422	0.000^b	4.419	2.052, 9.513
AFP	1.076	0.328	10.744	0.001^b	2.933	1.541, 5.582
BCLC stage			23.108	0.000^b
BCLC stage 1	0.339	0.704	0.232	0.6300	1.403	0.353, 5.572
BCLC stage 2	1.409	0.776	3.297	0.069	4.091	0.894, 18.718
BCLC stage 3	2.565	0.806	10.128	0.001^a	13.000	2.679, 63.093
CNLC stage			25.163	0.000^b
CNLC stage 1	1.313	0.457	8.259	0.004^b	3.716	1.518, 9.097
CNLC stage 1	2.309	0.501	21.218	0.000^b	10.065	3.768, 26.883
MVI	1.567	0.358	19.181	0.000^b	4.791	2.376, 9.658
Pathological satellite focus	1.263	0.513	6.066	0.014^b	3.534	1.294, 9.653
Tumor size	0.125	0.046	7.278	0.007^b	1.133	1.035, 1.241
Tumor numbers	0.912	0.394	5.352	0.021^a	2.489	1.149, 5.388
Tumor boundary	1.790	0.350	26.187	0.000^b	5.987	3.017, 11.882
Tumor capsule	0.581	0.247	5.549	0.018^a	1.788	1.103, 2.900
Intratumoral hemorrhage	0.728	0.374	3.784	0.052	2.070	0.995, 4.308
Intratumoral necrosis	1.274	0.337	14.265	0.000^b	3.577	1.846, 6.930
Portal vein tumor thrombus	2.232	0.778	8.230	0.004^b	9.317	2.028, 42.801
Large vessel invasion	2.217	0.521	18.090	0.000^b	9.183	3.305, 25.515
Nonperipheral washout	1.106	0.540	4.202	0.040^a	3.022	1.050, 8.701
Peritumoral enhancement	1.055	0.444	5.638	0.018^a	2.873	1.202, 6.864
HBP tumor SI/peritumoral SI	-0.035	0.012	8.688	0.003^b	0.965	0.943, 0.988
HBP peritumoral low signal	1.856	0.464	16.035	0.000^b	6.401	2.580, 15.882
Peritumoral delay enhancement	-1.795	0.518	12.017	0.001^b	0.166	0.060, 0.458

^aP < 0.05.

^bP < 0.01.

HR: Hazard ratio; 95%CI: 95% confidence interval; AFP: Alpha-fetoprotein; BCLC: Barcelona Clinic Liver Cancer; CNLC: China liver cancer; MVI: Microvascular invasion; SI: Signal intensity; HBP: Hepatobiliary phase.

Table 4 Multivariate logistic regression analysis to identify the predictors for early recurrence of hepatocellular carcinoma patients after operation

Factors	B	SE	Wald χ²	P value	HR	95%CI
Age (≤ 50 yr)	1.314	0.430	9.356	0.002^b	3.722	1.603, 8.641
MVI	0.828	0.422	3.846	0.050^a	2.288	1.001, 5.234
CNLC stage			12.193	0.002^b
Stage II	0.938	0.496	3.577	0.059	2.556	0.967, 6.757
Stage III	1.836	0.558	10.839	0.001^b	6.272	2.102, 18.712
Irregular shape	1.292	0.380	11.550	0.001^b	3.638	1.728, 7.663
Large vessel invasion	1.736	0.557	9.728	0.002^b	5.675	1.906, 16.896

^aP < 0.05.

^bP < 0.01.

HR: Hazard ratio; 95%CI: 95% confidence interval; CNLC: China liver cancer; MVI: Microvascular invasion.

Table 5 External validation of the predictors for early recurrence of hepatocellular carcinoma patients after operation

Factors	Sensitivity	Specificity	Accuracy	AUC	P value	95%CI
Age (≤ 50 yr)	0.500	0.882	0.710	0.691	0.071	0.496, 0.886
MVI	0.643	0.941	0.806	0.792	0.006	0.619, 0.965
CNLC stage (II-III)	0.571	0.941	0.774	0.756	0.015	0.574, 0.939
Irregular shape	0.643	0.824	0.742	0.733	0.028	0.548, 0.919
Large vessel invasion	0.500	0.941	0.742	0.721	0.037	0.530, 0.911
Combined multi-factors	0.786	0.941	0.871	0.861	0.001	0.717, 1.000

AUC: Area under the curve; 95%CI: 95% confidence interval; CNLC: China liver cancer; MVI: Microvascular invasion.

Citation: Chen JP, Yang RH, Zhang TH, Liao LA, Guan YT, Dai HY. Pre-operative enhanced magnetic resonance imaging combined with clinical features predict early recurrence of hepatocellular carcinoma after radical resection. World J Gastrointest Oncol 2024; 16(4): 1192-1203
URL: https://www.wjgnet.com/1948-5204/full/v16/i4/1192.htm
DOI: https://dx.doi.org/10.4251/wjgo.v16.i4.1192